Myasthenia Gravis Pipeline Analysis Report 2026

Report Coverage

The Myasthenia Gravis Pipeline Analysis Report by Expert Market Research gives comprehensive insights into myasthenia gravis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for myasthenia gravis. The myasthenia gravis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The myasthenia gravis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with myasthenia gravis treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to myasthenia gravis.

Read more about this report - Request a Free Sample

Myasthenia Gravis Pipeline Outlook

Myasthenia gravis is a rare, chronic autoimmune disorder that disrupts neuromuscular communication, leading to fluctuating muscle weakness. It is often categorized under neuromuscular junction disorders and involves autoantibodies such as anti-acetylcholine receptor (AChR) and anti-muscle-specific tyrosine kinase (MuSK), which interfere with nerve-to-muscle signaling.

Treatment strategies focus on symptom control and immune modulation, including acetylcholinesterase inhibitors, corticosteroids, immunosuppressants, plasma exchange, and emerging monoclonal antibody therapies for myasthenia gravis. In December 2025, the FDA approved UPLIZNA® (inebilizumab-cdon) for adults with generalized Myasthenia Gravis who are positive for AChR or MuSK antibodies. The twice-yearly CD19-targeted B cell therapy demonstrated durable efficacy in the Phase 3 MINT trial, reducing steroid dependence and improving daily functioning, marking a significant advancement in the pipeline.

Myasthenia Gravis Epidemiology

The epidemiology of myasthenia gravis highlights a growing patient base that is increasingly shaping therapeutic development. According to Fan Jiang et al., 2023, myasthenia gravis (MG) has a global incidence of 0.3-2.8 per 100,000 person-years. As per Amgen, approximately 85% of patients have the generalized form (gMG), with a global prevalence of 2-36 cases per 100,000. Around 85% have antibodies against the acetylcholine receptor (AChR), and 7% against MuSK. The disease is more common in women aged 20-30 and men over 50. The growing patient population is driving pipeline development.

Myasthenia Gravis - Pipeline Therapeutic Assessment

Myasthenia Gravis Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III 39% dominates the myasthenia gravis pipeline, driven by advanced clinical validation and strong commercialization potential, positively influencing market readiness. Phase II 26% reflects robust mid-stage innovation and efficacy optimization. Phase I 20% highlights growing early clinical exploration. Early phase I 8% indicates emerging research activity, while phase IV 7% supports post-marketing confidence and long-term therapeutic value.

Myasthenia Gravis Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the myasthenia gravis pipeline analysis include small molecules, monoclonal antibodies, gene therapies, peptides, and polymers. The myasthenia gravis report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for myasthenia gravis. Complement-targeted therapies are emerging as promising treatment options for generalized myasthenia gravis. For instance, cemdisiran, an investigational siRNA therapy targeting complement factor 5 (C5), is under evaluation as a monotherapy with quarterly dosing. Additionally, combination therapy cemdi-poze (cemdisiran + pozelimab) is being investigated to enhance complement inhibition and improve patient outcomes, reflecting advancements in complement inhibition therapy.

Myasthenia Gravis Clinical Trials - Key Players

The EMR report for the myasthenia gravis pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed myasthenia gravis therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in myasthenia gravis clinical trials:

• Immunovant Sciences GmbH
• ImmunAbs Inc.
• COUR Pharmaceutical Development Company, Inc.
• Shanghai Jiaolian Drug Research and Development Co., Ltd.
• NMD Pharma A/S
• Novartis Pharmaceuticals
• Dianthus Therapeutics
• CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
• Juno Therapeutics, Inc.
• Kyverna Therapeutics
• Janssen Research & Development, LLC
• UCB Biopharma SRL
• RemeGen Co., Ltd.

Myasthenia Gravis - Emerging Drugs Profile

Key Questions Answered in the Myasthenia Gravis Pipeline Insight Report

• Which companies/institutions are leading myasthenia gravis drug development?
• Which company is leading the myasthenia gravis pipeline development activities?
• What is the current myasthenia gravis commercial assessment?
• What are the opportunities and challenges present in the myasthenia gravis pipeline landscape?
• What is the efficacy and safety profile of myasthenia gravis pipeline drugs?
• Which company is conducting major trials for myasthenia gravis drugs?
• Which companies/institutions are involved in myasthenia gravis collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in myasthenia gravis?

Reasons To Buy This Report

The Myasthenia Gravis Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for myasthenia gravis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into myasthenia gravis collaborations, regulatory environments, and potential growth opportunities.

Related Reports

Clinical Trials Market

Myasthenia Gravis Epidemiology Forecast